ResMed (NYSE:RMD) Stock Price, News, Analysis & History

$95.57 -0.91 (-0.94 %)
(As of 03/23/2018 04:00 PM ET)
Previous Close$96.48
Today's Range$95.38 - $97.37
52-Week Range$67.04 - $104.78
Volume555,676 shs
Average Volume718,646 shs
Market Capitalization$14.05 billion
P/E Ratio47.71
Dividend Yield1.42%

About ResMed (NYSE:RMD)

ResMed logoResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions. The Company produces Continuous Positive Airway Pressure (CPAP), Variable Positive Airway Pressure (VPAP) and AutoSet systems for the titration and treatment of SDB.

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry MED PRODS
Sub-IndustryHealth Care Equipment


Debt-to-Equity RatioN/A
Current Ratio1.29%
Quick Ratio1.08%


Trailing P/E Ratio47.71
Forward P/E Ratio28.61
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.07 billion
Price / Sales6.61
Cash Flow$3.52 per share
Price / Cash27.16
Book Value$13.82 per share
Price / Book6.92


Trailing EPS$2.00
Net Income$342.28 million
Net Margins12.98%
Return on Equity22.75%
Return on Assets12.86%


Outstanding Shares142,930,000

ResMed (NYSE:RMD) Frequently Asked Questions

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Monday, January 22nd. Stockholders of record on Thursday, February 8th will be given a dividend of $0.35 per share on Thursday, March 15th. This represents a $1.40 annualized dividend and a dividend yield of 1.46%. The ex-dividend date of this dividend is Wednesday, February 7th. View ResMed's Dividend History.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) released its earnings results on Monday, January, 22nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.78 by $0.22. The medical equipment provider had revenue of $601.27 million for the quarter, compared to the consensus estimate of $583.77 million. ResMed had a net margin of 12.98% and a return on equity of 22.75%. The business's revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.73 EPS. View ResMed's Earnings History.

When will ResMed make its next earnings announcement?

ResMed is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for ResMed.

Where is ResMed's stock going? Where will ResMed's stock price be in 2018?

11 brokerages have issued twelve-month price objectives for ResMed's shares. Their forecasts range from $55.00 to $90.00. On average, they anticipate ResMed's stock price to reach $68.80 in the next year. View Analyst Ratings for ResMed.

What are Wall Street analysts saying about ResMed stock?

Here are some recent quotes from research analysts about ResMed stock:

  • 1. According to Zacks Investment Research, "Over the past three months, ResMed has outperformed its industry. We are encouraged to note that ResMed is working on product innovation through extensive research and development. Among the recent developments, the company recently informed about its first self-branded portable oxygen concentrator Mobi, subject to a fiscal third-quarter launch. It has also introduced AirMini, the world's smallest PAP device. Moreover, the company achieved solid double-digit global revenue growth in the last reported quarter, led by sales from Software-as-a-Service business as well as mask products and devices. Yet, challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations. Rising costs and a weak gross margin are other concerns." (3/8/2018)
  • 2. Needham & Company LLC analysts commented, "We worked with Sleep Review magazine to survey US sleep centers. The survey included 136 responses received between 1/30/18 and 2/19/18. Compared to our prior (3Q17) survey, actual last-12-month patient volume growth decreased slightly while expected next-12-month patient volume growth increased slightly. RMD’s flow generator ratings were in line with Respironics’ ratings while RMD’s mask ratings were the highest but only slightly above its competitors’ ratings. RMD looks likely to gain branded flow generator prescription share but to lose branded mask prescription share. Overall, we think that the survey is mixed for RMD and we maintain our Hold rating." (3/7/2018)

Who are some of ResMed's key competitors?

Who are ResMed's key executives?

ResMed's management team includes the folowing people:

  • Peter C. Farrell Ph.D., Non-Executive Chairman of the Board, Founder (Age 75)
  • Rob Douglas, President, Chief Operating Officer (Age 57)
  • Michael Farrell, Chief Executive Officer, Director (Age 45)
  • Brett A. Sandercock, Chief Financial Officer (Age 50)
  • Jim Hollingshead Ph.D., President – Sleep Business (Age 54)
  • Richard McHale, President – Respiratory Care (Age 53)
  • Raj Sodhi, President – Software as a Service (SaaS) Business and Chief Technology Officer (Age 44)
  • David Pendarvis, Chief Administrative Officer, Global General Counsel, Company Secretary (Age 57)
  • Ronald R. Taylor, Lead Independent Director (Age 69)
  • Karen Drexler, Director (Age 56)

Has ResMed been receiving favorable news coverage?

Press coverage about RMD stock has trended somewhat positive on Friday, according to Accern Sentiment. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ResMed earned a media sentiment score of 0.17 on Accern's scale. They also gave news headlines about the medical equipment provider an impact score of 48.06 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are ResMed's major shareholders?

ResMed's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.80%), Geode Capital Management LLC (1.21%), Bank of New York Mellon Corp (1.19%), Congress Asset Management Co. MA (0.75%), Matthews International Capital Management LLC (0.51%) and Guggenheim Capital LLC (0.51%). Company insiders that own ResMed stock include Brett Sandercock, Christopher G Roberts, David Pendarvis, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Mchale, Richard Sulpizio, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

Which major investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Quantitative Investment Management LLC, First Trust Advisors LP, Swiss National Bank, Matthews International Capital Management LLC, Metropolitan Life Insurance Co. NY, Bank of New York Mellon Corp and Professional Advisory Services Inc.. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Peter C Farrell, Richard Mchale, Richard Sulpizio and Ronald R Taylor. View Insider Buying and Selling for ResMed.

Which major investors are buying ResMed stock?

RMD stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Guggenheim Capital LLC, Macquarie Group Ltd., Schroder Investment Management Group, Amundi Pioneer Asset Management Inc., Geode Capital Management LLC, WINTON GROUP Ltd and MetLife Investment Advisors LLC. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert, Ronald R Taylor and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $95.57.

How big of a company is ResMed?

ResMed has a market capitalization of $14.05 billion and generates $2.07 billion in revenue each year. The medical equipment provider earns $342.28 million in net income (profit) each year or $2.00 on an earnings per share basis. ResMed employs 6,080 workers across the globe.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]

MarketBeat Community Rating for ResMed (RMD)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  451 (Vote Underperform)
Total Votes:  662
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ResMed (NYSE:RMD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score:
Ratings Breakdown: 3 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $68.80$68.80$65.83$64.67
Price Target Upside: 28.01% downside21.38% downside23.84% downside17.96% downside

ResMed (NYSE:RMD) Consensus Price Target History

Price Target History for ResMed (NYSE:RMD)

ResMed (NYSE:RMD) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2018Needham & Company LLCReiterated RatingHoldMediumView Rating Details
1/23/2018Northland SecuritiesUpgradeUnder Perform -> Market PerformHighView Rating Details
1/23/2018MacquarieDowngradeNeutral -> SellHighView Rating Details
1/23/2018BMO Capital MarketsBoost Price TargetMarket Perform$90.00HighView Rating Details
10/30/2017JPMorgan Chase & Co.Boost Price TargetOverweight$72.00 -> $73.00N/AView Rating Details
10/27/2017BarclaysBoost Price TargetUnderweight$68.00 -> $70.00N/AView Rating Details
10/12/2017Jefferies GroupReiterated RatingSell$56.00N/AView Rating Details
8/8/2017Credit Suisse GroupDowngradeOutperform -> NeutralLowView Rating Details
8/2/2017CitigroupUpgradeNeutral -> BuyHighView Rating Details
8/2/2017Bank of AmericaDowngradeBuy -> NeutralHighView Rating Details
4/13/2017William BlairReiterated RatingOutperformLowView Rating Details
2/6/2017Canaccord GenuityReiterated RatingHold$59.00N/AView Rating Details
4/27/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$65.00 -> $57.00N/AView Rating Details
(Data available from 3/23/2016 forward)


ResMed (NYSE:RMD) Earnings History and Estimates Chart

Earnings by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE RMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018$0.84N/AView Earnings Details
1/22/2018Q2 2018$0.78$1.00$583.77 million$601.27 millionViewListenView Earnings Details
10/26/2017Q1 2018$0.66$0.66$506.08 million$523.66 millionViewN/AView Earnings Details
8/1/2017Q4 2017$0.75$0.77$557.68 million$556.69 millionViewListenView Earnings Details
4/27/2017Q3 2017$0.70$0.71$525.84 million$514.20 millionViewN/AView Earnings Details
1/23/2017Q217$0.70$0.73$518.60 million$530.40 millionViewN/AView Earnings Details
10/25/2016Q117$0.64$0.62$475.05 million$465.45 millionViewListenView Earnings Details
7/28/2016Q416$0.74$0.74$512.37 million$518.60 millionViewListenView Earnings Details
4/26/2016Q316$0.69$0.68$455.32 million$453.90 millionViewListenView Earnings Details
1/21/2016Q216$0.66$0.69$445.46 million$454.54 millionViewListenView Earnings Details
10/22/2015Q116$0.59$0.58$406.26 million$411.70 millionViewListenView Earnings Details
7/30/2015Q415$0.65$0.68$436.27 million$453.10 millionViewListenView Earnings Details
4/23/2015Q315$0.65$0.65$425.76 million$422.50 millionViewListenView Earnings Details
1/22/2015Q215$0.62$0.64$408.20 million$423.00 millionViewListenView Earnings Details
10/23/2014Q115$0.58$0.58$375.00 million$380.40 millionViewListenView Earnings Details
7/31/2014Q414$0.66$0.64$433.42 million$415.20 millionViewListenView Earnings Details
4/23/2014Q314$0.64$0.63$401.00 million$397.80 millionViewListenView Earnings Details
1/23/2014Q214$0.63$0.60$398.09 million$384.30 millionViewListenView Earnings Details
10/24/2013Q114$0.58$0.56$372.28 million$357.66 millionViewListenView Earnings Details
8/1/2013Q4 2013$0.62$0.62$410.89 million$414.60 millionViewListenView Earnings Details
4/25/2013Q3 2013$0.58$0.58$386.76 million$383.60 millionViewListenView Earnings Details
1/24/2013Q2 2013$0.51$0.53$363.76 million$376.50 millionViewListenView Earnings Details
10/25/2012$0.46$0.49ViewN/AView Earnings Details
8/2/2012$0.49$0.53ViewN/AView Earnings Details
4/26/2012$0.41$0.44ViewN/AView Earnings Details
1/26/2012$0.38$0.42ViewN/AView Earnings Details
10/24/2011$0.35$0.33ViewN/AView Earnings Details
8/4/2011$0.37$0.37ViewN/AView Earnings Details
4/28/2011$0.35$0.35ViewN/AView Earnings Details
1/27/2011$0.36$0.37ViewN/AView Earnings Details
10/28/2010Q1 2011$0.32$0.36ViewN/AView Earnings Details
8/5/2010Q4 2010$0.33$0.34ViewN/AView Earnings Details
4/29/2010Q3 2010$0.29$0.32ViewN/AView Earnings Details
2/4/2010Q2 2010$0.28$0.31ViewN/AView Earnings Details
11/5/2009Q1 2010$0.25$0.29ViewN/AView Earnings Details
8/6/2009Q4 2009$0.27$0.31ViewN/AView Earnings Details
5/7/2009Q3 2009$0.23$0.25ViewN/AView Earnings Details
2/5/2009Q2 2009$0.21$0.22ViewN/AView Earnings Details
11/6/2008Q1 2009$0.19$0.18ViewN/AView Earnings Details
8/5/2008Q4 2008$0.19$0.19ViewN/AView Earnings Details
5/1/2008Q3 2008$0.20$0.19ViewN/AView Earnings Details
2/7/2008Q2 2008$0.20$0.18ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


ResMed (NYSE:RMD) Earnings Estimates

2018 EPS Consensus Estimate: $3.04
2019 EPS Consensus Estimate: $3.33
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.63$0.65$0.64
Q2 20182$0.74$0.77$0.76
Q3 20182$0.79$0.79$0.79
Q4 20182$0.85$0.85$0.85
Q1 20192$0.72$0.76$0.74
Q2 20192$0.86$0.89$0.88
Q3 20192$0.82$0.83$0.83
Q4 20192$0.86$0.92$0.89
(Earnings estimates data provided by Zacks Investment Research)


ResMed (NYSE:RMD) Dividend Information

Most Recent Dividend:3/15/2018
Annual Dividend:$1.40
Dividend Yield:1.46%
Dividend Growth:8.70% (3 Year Average)
Payout Ratio:70.00% (Trailing 12 Months of Earnings)
41.92% (Based on This Year's Estimates)
40.23% (Based on Next Year's Estimates)
Track Record:2 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE:RMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ResMed (NYSE RMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.77%
Institutional Ownership Percentage: 62.40%
Insider Trades by Quarter for ResMed (NYSE:RMD)
Institutional Ownership by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE RMD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018Brett SandercockCFOSell2,000$98.53$197,060.0073,072View SEC Filing  
3/5/2018David PendarvisInsiderSell2,810$94.08$264,364.8097,263View SEC Filing  
3/1/2018James HollingsheadInsiderSell600$94.01$56,406.00View SEC Filing  
2/15/2018Brett SandercockCFOSell2,000$93.42$186,840.0075,072View SEC Filing  
2/5/2018David PendarvisInsiderSell2,810$96.03$269,844.3097,263View SEC Filing  
2/1/2018Brett SandercockCFOSell1,250$100.13$125,162.5077,072View SEC Filing  
2/1/2018Richard MchaleInsiderSell2,000$100.12$200,240.0062,002View SEC Filing  
1/26/2018John P WarehamDirectorSell25,934$102.25$2,651,751.5038,934View SEC Filing  
1/24/2018Ronald R TaylorDirectorSell4,885$99.71$487,083.3521,751View SEC Filing  
1/2/2018Brett SandercockCFOSell1,250$84.99$106,237.5078,322View SEC Filing  
1/2/2018James HollingsheadInsiderSell600$84.96$50,976.0062,602View SEC Filing  
12/4/2017David PendarvisInsiderSell2,804$84.17$236,012.6897,257View SEC Filing  
12/1/2017Brett SandercockCFOSell1,250$85.36$106,700.0079,572View SEC Filing  
11/20/2017James HollingsheadInsiderSell7,019$84.16$590,719.0466,409View SEC Filing  
11/9/2017Peter C FarrellDirectorSell118,392$82.70$9,791,018.40306,615View SEC Filing  
11/6/2017Peter C FarrellDirectorSell20,000$83.53$1,670,600.00314,800View SEC Filing  
11/3/2017David PendarvisInsiderSell6,364$82.20$523,120.80View SEC Filing  
11/1/2017Brett SandercockCFOSell1,250$84.50$105,625.0071,772View SEC Filing  
10/4/2017Peter C FarrellDirectorSell20,000$77.01$1,540,200.00View SEC Filing  
10/3/2017David PendarvisInsiderSell6,364$76.94$489,646.16View SEC Filing  
10/2/2017Brett SandercockCFOSell1,250$77.05$96,312.5064,691View SEC Filing  
9/5/2017David PendarvisInsiderSell6,364$77.21$491,364.4493,172View SEC Filing  
9/5/2017Peter C FarrellDirectorSell20,000$76.74$1,534,800.00314,800View SEC Filing  
9/1/2017Brett SandercockCFOSell1,250$77.56$96,950.0065,941View SEC Filing  
8/9/2017Richard SulpizioDirectorSell24,390$73.85$1,801,201.5028,819View SEC Filing  
8/4/2017Peter C FarrellDirectorSell20,000$75.15$1,503,000.00321,557View SEC Filing  
8/3/2017David PendarvisInsiderSell6,364$72.10$458,844.4084,476View SEC Filing  
8/1/2017Brett SandercockCFOSell1,250$77.49$96,862.5059,258View SEC Filing  
7/14/2017James HollingsheadInsiderSell7,140$77.43$552,850.20View SEC Filing  
7/5/2017Peter C FarrellDirectorSell20,000$76.50$1,530,000.00321,557View SEC Filing  
7/3/2017Brett SandercockCFOSell1,250$77.44$96,800.0060,508View SEC Filing  
7/3/2017David PendarvisInsiderSell6,364$77.36$492,319.0484,476View SEC Filing  
6/29/2017Jr. Gregor K EmmertInsiderBuy282,000$0.07$19,740.00
6/28/2017Jr. Gregor K EmmertInsiderBuy424,000$0.06$25,440.00
6/22/2017Richard SulpizioDirectorSell65,887$77.82$5,127,326.344,429View SEC Filing  
6/15/2017Gary W PaceDirectorSell24,390$76.00$1,853,640.0099,317View SEC Filing  
6/5/2017David PendarvisInsiderSell6,365$72.62$462,226.3084,477View SEC Filing  
6/5/2017Peter C FarrellDirectorSell20,000$72.65$1,453,000.00321,557View SEC Filing  
6/1/2017Brett SandercockCFOSell1,250$71.02$88,775.00View SEC Filing  
5/4/2017Peter C FarrellDirectorSell20,000$68.75$1,375,000.00321,557View SEC Filing  
5/3/2017David PendarvisInsiderSell6,365$69.55$442,685.7584,261View SEC Filing  
5/1/2017Brett SandercockCFOSell1,250$68.60$85,750.0062,783View SEC Filing  
4/17/2017James HollingsheadInsiderSell7,139$68.37$488,093.4344,934View SEC Filing  
4/4/2017Peter C FarrellDirectorSell20,000$70.67$1,413,400.00321,557View SEC Filing  
4/3/2017Brett SandercockCFOSell1,250$71.65$89,562.5064,033View SEC Filing  
4/3/2017David PendarvisInsiderSell6,365$71.59$455,670.3584,261View SEC Filing  
3/1/2017Brett SandercockCFOSell1,250$72.48$90,600.0065,283View SEC Filing  
2/24/2017John P WarehamDirectorSell28,403$71.77$2,038,483.3141,403View SEC Filing  
2/20/2017Christopher G RobertsDirectorSell10,000$71.91$719,100.00145,610View SEC Filing  
2/15/2017Franz KozichDirectorBuy50,000$0.05$2,500.00
2/14/2017Warren Russell HawkinsDirectorBuy60,000$0.05$3,000.00
2/6/2017Peter C FarrellDirectorSell20,000$68.32$1,366,400.00321,557View SEC Filing  
2/3/2017David PendarvisInsiderSell6,365$67.16$427,473.4084,261View SEC Filing  
1/17/2017James HollingsheadInsiderSell7,084$64.44$456,492.9646,754View SEC Filing  
1/4/2017Peter C FarrellDirectorSell20,000$62.14$1,242,800.00321,557View SEC Filing  
1/3/2017David PendarvisInsiderSell6,365$61.95$394,311.7584,261View SEC Filing  
12/5/2016David PendarvisInsiderSell6,365$60.00$381,900.0084,261View SEC Filing  
12/5/2016Peter C FarrellDirectorSell20,000$59.83$1,196,600.00372,407View SEC Filing  
11/4/2016Peter C FarrellDirectorSell20,000$57.28$1,145,600.00367,978View SEC Filing  
11/3/2016David PendarvisInsiderSell6,033$57.79$348,647.07View SEC Filing  
10/18/2016James HollingsheadInsiderSell1,967$64.71$127,284.5745,513View SEC Filing  
10/17/2016James HollingsheadInsiderSell5,264$64.43$339,159.5252,744View SEC Filing  
10/17/2016Michael J FarrellCEOSell5,975$64.25$383,893.75203,781View SEC Filing  
10/4/2016Peter C FarrellDirectorSell20,000$64.70$1,294,000.00364,063View SEC Filing  
10/3/2016David PendarvisInsiderSell6,000$63.95$383,700.0087,061View SEC Filing  
9/15/2016Michael J. FarrellCEOSell5,975$64.84$387,419.00View SEC Filing  
9/6/2016David PendarvisInsiderSell6,000$67.18$403,080.0087,061View SEC Filing  
9/6/2016Peter C FarrellDirectorSell20,000$67.29$1,345,800.00367,978View SEC Filing  
8/19/2016Gary W PaceDirectorSell36,000$69.93$2,517,480.00129,158View SEC Filing  
8/17/2016Ronald R TaylorDirectorBuy2,487$69.13$171,926.3116,729View SEC Filing  
8/16/2016Ronald R TaylorDirectorSell23,102$69.25$1,599,813.5016,729View SEC Filing  
8/15/2016Michael J. FarrellCEOSell5,975$70.41$420,699.75View SEC Filing  
8/11/2016Brett SandercockCFOSell35,000$70.50$2,467,500.00View SEC Filing  
8/10/2016Richard SulpizioDirectorSell36,000$70.15$2,525,400.00101,887View SEC Filing  
8/8/2016John P WarehamDirectorSell24,390$70.32$1,715,104.8037,390View SEC Filing  
8/4/2016Peter C FarrellDirectorSell20,000$69.16$1,383,200.00367,978View SEC Filing  
8/3/2016David PendarvisInsiderSell6,000$68.86$413,160.0080,512View SEC Filing  
7/15/2016Michael J FarrellCEOSell5,975$65.03$388,554.25154,814View SEC Filing  
7/14/2016James HollingsheadInsiderSell2,753$65.02$179,000.0640,669View SEC Filing  
7/7/2016Peter C FarrellDirectorSell20,000$63.62$1,272,400.00367,978View SEC Filing  
7/5/2016David PendarvisInsiderSell6,000$63.62$381,720.0080,512View SEC Filing  
6/15/2016James HollingsheadInsiderSell4,458$59.40$264,805.2043,422View SEC Filing  
6/15/2016Michael J FarrellCEOSell5,975$59.63$356,289.25154,814View SEC Filing  
6/6/2016Peter C FarrellDirectorSell20,000$59.82$1,196,400.00367,978View SEC Filing  
6/3/2016David PendarvisInsiderSell6,000$59.41$356,460.0080,512View SEC Filing  
5/16/2016Michael J FarrellCEOSell5,975$57.64$344,399.00154,723View SEC Filing  
5/4/2016Peter C FarrellDirectorSell20,000$55.90$1,118,000.00367,978View SEC Filing  
5/3/2016David PendarvisInsiderSell6,000$56.02$336,120.0080,287View SEC Filing  
4/15/2016Michael J FarrellCEOSell5,975$59.34$354,556.50154,723View SEC Filing  
4/4/2016David PendarvisInsiderSell6,000$58.70$352,200.0080,287View SEC Filing  
4/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00367,978View SEC Filing  
3/15/2016James HollingsheadInsiderSell4,500$58.57$263,565.0047,569View SEC Filing  
3/15/2016Michael J FarrellCEOSell5,975$58.57$349,955.75150,852View SEC Filing  
3/11/2016Gary W PaceDirectorSell36,000$60.00$2,160,000.00129,158View SEC Filing  
3/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00367,978View SEC Filing  
3/3/2016David PendarvisInsiderSell6,000$57.26$343,560.0080,287View SEC Filing  
2/29/2016Anne ReiserInsiderSell1,946$57.06$111,038.7676,300View SEC Filing  
2/26/2016Brett SandercockCFOSell30,000$57.61$1,728,300.00132,136View SEC Filing  
2/26/2016Richard SulpizioDirectorSell36,000$57.88$2,083,680.00101,887View SEC Filing  
2/25/2016Peter C FarrellDirectorSell139,980$57.31$8,022,253.80347,978View SEC Filing  
2/16/2016Michael J. FarrellCEOSell5,975$58.20$347,745.00144,878View SEC Filing  
2/4/2016Peter C. FarrellDirectorSell20,000$57.70$1,154,000.00347,978View SEC Filing  
2/3/2016David PendarvisinsiderSell6,000$57.43$344,580.0074,287View SEC Filing  
1/27/2016Franz KozichDirectorBuy60,000$0.04$2,100.00
1/15/2016Michael J. FarrellCEOSell5,975$53.07$317,093.25144,878View SEC Filing  
1/4/2016David PendarvisinsiderSell6,000$52.16$312,960.0074,287View SEC Filing  
1/4/2016Peter C. FarrellDirectorSell20,000$52.22$1,044,400.00347,978View SEC Filing  
1/4/2016Robert Andrew DouglasCOOSell6,337$52.97$335,670.8931,304View SEC Filing  
12/15/2015James HollingsheadInsiderSell4,500$55.95$251,775.0052,069View SEC Filing  
12/3/2015David PendarvisinsiderSell6,000$59.38$356,280.0074,287View SEC Filing  
12/1/2015Robert Andrew DouglasCOOSell6,333$59.77$378,523.4131,304View SEC Filing  
11/25/2015Warren Russell HawkinsDirectorBuy15,000$0.06$825.00
11/24/2015Warren Russell HawkinsDirectorBuy3,000$0.06$165.00
11/20/2015Christopher G RobertsDirectorSell12,000$59.03$708,360.00109,610View SEC Filing  
11/16/2015Michael J. FarrellCEOSell5,975$57.03$340,754.25144,878View SEC Filing  
11/12/2015Donald DarkininsiderSell25,442$57.72$1,468,512.2413,684View SEC Filing  
11/2/2015Robert Andrew DouglasCOOSell6,333$57.60$364,780.8068,391View SEC Filing  
10/27/2015Anne ReiserinsiderSell3,000$57.01$171,030.0083,214View SEC Filing  
10/15/2015Michael J. FarrellCEOSell5,975$55.35$330,716.25172,370View SEC Filing  
10/5/2015David PendarvisinsiderSell5,500$52.47$288,585.0077,180View SEC Filing  
10/5/2015Robert Andrew DouglasCOOSell6,333$52.13$330,139.2968,179View SEC Filing  
10/1/2015Peter C. FarrellChairmanSell27,169$50.93$1,383,717.17289,826View SEC Filing  
9/15/2015James HollingsheadInsiderSell4,455$50.67$225,734.8567,680View SEC Filing  
9/15/2015Michael J. FarrellCEOSell5,975$50.89$304,067.75172,370View SEC Filing  
9/3/2015David PendarvisinsiderSell5,500$51.78$284,790.0077,180View SEC Filing  
9/3/2015Robert Andrew DouglasCOOSell6,333$52.04$329,569.3275,316View SEC Filing  
9/1/2015Peter C. FarrellChairmanSell36,000$50.82$1,829,520.00289,826View SEC Filing  
8/28/2015Anne ReiserinsiderSell6,000$52.26$313,560.0083,214View SEC Filing  
8/27/2015Richard SulpizioDirectorSell10,860$51.83$562,873.8061,527View SEC Filing  
8/17/2015Michael J FarrellCEOSell5,975$55.54$331,851.50View SEC Filing  
7/15/2015Michael J FarrellCEOSell5,975$57.59$344,100.25View SEC Filing  
7/6/2015David PendarvisInsiderSell5,500$55.19$303,545.00View SEC Filing  
7/1/2015Peter C FarrellChairmanSell36,000$55.61$2,001,960.00View SEC Filing  
7/1/2015Robert Andrew DouglasCOOSell6,333$56.59$358,384.47View SEC Filing  
6/15/2015Michael J FarrellCEOSell5,975$57.87$345,773.25View SEC Filing  
6/3/2015David PendarvisInsiderSell5,500$59.41$326,755.00View SEC Filing  
6/1/2015Peter C FarrellChairmanSell36,000$59.25$2,133,000.00View SEC Filing  
6/1/2015Robert Andrew DouglasCOOSell6,333$59.22$375,040.26View SEC Filing  
5/4/2015David PendarvisInsiderSell5,500$65.10$358,050.00View SEC Filing  
4/6/2015David PendarvisInsiderSell5,500$72.60$399,300.00View SEC Filing  
4/1/2015Peter C FarrellChairmanSell36,000$70.70$2,545,200.00View SEC Filing  
4/1/2015Robert Andrew DouglasCOOSell6,333$70.67$447,553.11View SEC Filing  
3/27/2015Warren Russell HawkinsDirectorBuy10,000$0.09$900.00
3/26/2015Warren Russell HawkinsDirectorBuy10,000$0.08$800.00
3/16/2015Anne ReiserInsiderSell4,000$69.10$276,400.00View SEC Filing  
3/16/2015Michael J FarrellCEOSell5,975$69.10$412,872.50View SEC Filing  
3/9/2015Anne ReiserInsiderSell3,000$66.75$200,250.00View SEC Filing  
3/2/2015Peter C FarrellChairmanSell36,000$64.64$2,327,040.00View SEC Filing  
3/2/2015Robert Andrew DouglasCOOSell6,333$64.39$407,781.87View SEC Filing  
2/17/2015Anne ReiserInsiderSell5,000$66.11$330,550.00View SEC Filing  
2/5/2015David PendarvisInsiderSell5,500$62.35$342,925.00View SEC Filing  
2/4/2015John P WarehamDirectorSell36,000$63.49$2,285,640.00View SEC Filing  
2/3/2015Brett SandercockCFOSell18,670$62.82$1,172,849.40View SEC Filing  
2/3/2015Robert Andrew DouglasCOOSell6,333$62.35$394,862.55View SEC Filing  
2/2/2015Peter C FarrellChairmanSell36,000$61.97$2,230,920.00View SEC Filing  
1/26/2015Gary W PaceDirectorSell48,000$66.77$3,204,960.00View SEC Filing  
1/5/2015David PendarvisInsiderSell5,500$57.09$313,995.00View SEC Filing  
1/2/2015Peter C FarrellChairmanSell36,000$56.99$2,051,640.00View SEC Filing  
1/2/2015Robert Andrew DouglasCOOSell8,000$56.99$455,920.00View SEC Filing  
12/1/2014Peter C FarrellChairmanSell36,000$53.28$1,918,080.00View SEC Filing  
12/1/2014Robert Andrew DouglasCOOSell8,000$52.93$423,440.00View SEC Filing  
11/18/2014Peter C FarrellChairmanSell36,000$52.39$1,886,040.00View SEC Filing  
11/3/2014David PendarvisInsiderSell3,557$52.00$184,964.00View SEC Filing  
11/3/2014Robert Andrew DouglasCOOSell8,000$51.84$414,720.00View SEC Filing  
10/29/2014Peter C FarrellChairmanSell119,204$51.84$6,179,535.36View SEC Filing  
10/3/2014David PendarvisInsiderSell5,000$49.84$249,200.00View SEC Filing  
10/1/2014Robert Andrew DouglasCOOSell8,000$49.11$392,880.00View SEC Filing  
9/15/2014Michael J FarrellCEOSell3,200$52.41$167,712.00View SEC Filing  
9/5/2014Brett SandercockCFOSell10,000$52.99$529,900.00View SEC Filing  
9/3/2014Brett SandercockCFOSell10,000$53.23$532,300.00View SEC Filing  
9/3/2014David PendarvisInsiderSell5,000$53.23$266,150.00View SEC Filing  
8/22/2014Anne ReiserInsiderSell3,000$53.37$160,110.00View SEC Filing  
8/4/2014David PendarvisInsiderSell5,000$49.12$245,600.00View SEC Filing  
8/1/2014Peter C FarrellDirectorSell25,000$49.04$1,226,000.00View SEC Filing  
8/1/2014Robert Andrew DouglasCOOSell8,000$48.95$391,600.00View SEC Filing  
7/15/2014Michael J FarrellCEOSell3,200$49.22$157,504.00View SEC Filing  
7/3/2014David PendarvisInsiderSell5,000$50.04$250,200.00View SEC Filing  
7/1/2014Peter C FarrellDirectorSell25,000$50.09$1,252,250.00View SEC Filing  
7/1/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
6/16/2014Michael J FarrellCEOSell3,200$53.20$170,240.00View SEC Filing  
6/3/2014David PendarvisInsiderSell5,000$49.76$248,800.00View SEC Filing  
6/2/2014Peter C FarrellDirectorSell25,000$49.57$1,239,250.00View SEC Filing  
6/2/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
5/29/2014Christopher G RobertsDirectorSell25,000$49.73$1,243,250.00View SEC Filing  
5/15/2014Michael FarrellCEOSell3,700$50.54$186,998.00106,655View SEC Filing  
5/13/2014John WarehamDirectorSell18,000$51.00$918,000.0013,000View SEC Filing  
5/8/2014Brett SandercockCFOSell5,000$50.00$250,000.0066,423View SEC Filing  
5/6/2014Brett SandercockCFOSell4,290$50.00$214,500.0071,423View SEC Filing  
5/1/2014Peter FarrellDirectorSell25,000$49.80$1,245,000.00304,990View SEC Filing  
5/1/2014Robert Andrew DouglasCOOSell8,000$49.75$398,000.00View SEC Filing  
4/29/2014David PendarvisInsiderSell15,000$50.01$750,150.0068,956View SEC Filing  
4/21/2014Peter FarrellDirectorSell75,000$48.01$3,600,750.00304,990View SEC Filing  
4/4/2014David PendarvisInsiderSell5,000$44.95$224,750.0068,956View SEC Filing  
2/12/2014Brett SandercockCFOSell10,687$46.00$491,602.0084,215View SEC Filing  
1/9/2014Peter FarrellDirectorSell25,000$48.00$1,200,000.00489,876View SEC Filing  
12/2/2013Robert Andrew DouglasCOOSell8,000$49.10$392,800.00100,572View SEC Filing  
11/20/2013Brett SandercockCFOSell15,000$51.06$765,900.0094,902View SEC Filing  
11/20/2013James HollingsheadInsiderSell4,000$51.24$204,960.0026,285View SEC Filing  
11/12/2013Donald DarkinInsiderSell31,063$50.04$1,554,392.5218,588View SEC Filing  
10/29/2013David PendarvisInsiderSell37,744$50.42$1,903,052.48View SEC Filing  
10/1/2013Peter C FarrellDirectorSell25,000$53.21$1,330,250.00View SEC Filing  
10/1/2013Robert Andrew DouglasCOOSell8,000$53.20$425,600.00View SEC Filing  
9/9/2013Gary W PaceDirectorSell12,000$50.05$600,600.00View SEC Filing  
9/5/2013Peter C FarrellDirectorSell25,000$48.00$1,200,000.00View SEC Filing  
9/3/2013Robert Andrew DouglasCOOSell8,000$47.51$380,080.00123,892View SEC Filing  
8/28/2013Michael QuinnDirectorSell48,000$48.34$2,320,320.00880,000View SEC Filing  
8/27/2013Brett SandercockCFOSell5,000$49.00$245,000.00109,012View SEC Filing  
8/26/2013Christopher RobertsDirectorSell10,000$49.49$494,900.0090,000View SEC Filing  
8/1/2013Robert Andrew DouglasCOOSell8,000$48.57$388,560.00View SEC Filing  
6/3/2013Robert Andrew DouglasCOOSell8,000$47.96$383,680.00View SEC Filing  
5/24/2013Christopher G RobertsDirectorSell20,000$49.45$989,000.00View SEC Filing  
5/22/2013John P WarehamDirectorSell18,000$50.20$903,600.00View SEC Filing  
5/13/2013Michael A QuinnDirectorSell15,000$50.94$764,100.00View SEC Filing  
5/8/2013Brett SandercockCFOSell28,000$48.97$1,371,160.00View SEC Filing  
2/4/2013Robert Andrew DouglasCOOSell8,000$44.14$353,120.00View SEC Filing  
8/8/2012Michael J FarrellInsiderSell30,000$35.58$1,067,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


ResMed (NYSE RMD) News Headlines

Zacks: Analysts Expect ResMed Inc. (RMD) Will Post Quarterly Sales of $562.33 MillionZacks: Analysts Expect ResMed Inc. (RMD) Will Post Quarterly Sales of $562.33 Million - March 22 at 5:34 AM
Brett Sandercock Sells 2,000 Shares of ResMed Inc. (RMD) StockBrett Sandercock Sells 2,000 Shares of ResMed Inc. (RMD) Stock - March 19 at 1:34 PM
Global Respiratory Care Devices Market Opportunities 2018: AstraZeneca PLC, ResMed, 3M, Medtronic, GE Healthcare, GlaxoSmithKlineGlobal Respiratory Care Devices Market Opportunities 2018: AstraZeneca PLC, ResMed, 3M, Medtronic, GE Healthcare, GlaxoSmithKline - March 14 at 9:27 AM
ResMed (RMD) Downgraded to Hold at Zacks Investment ResearchResMed (RMD) Downgraded to Hold at Zacks Investment Research - March 8 at 12:52 PM
ResMed (RMD) Rides High on Robust Global Growth & Innovation - NasdaqResMed (RMD) Rides High on Robust Global Growth & Innovation - Nasdaq - March 7 at 5:54 PM
Insider Selling: ResMed Inc. (RMD) Insider Sells 2,810 Shares of StockInsider Selling: ResMed Inc. (RMD) Insider Sells 2,810 Shares of Stock - March 7 at 3:15 PM
Needham & Company LLC Reaffirms Hold Rating for ResMed (RMD)Needham & Company LLC Reaffirms Hold Rating for ResMed (RMD) - March 7 at 2:50 PM
ResMed Inc. (RMD) Receives Consensus Recommendation of "Hold" from BrokeragesResMed Inc. (RMD) Receives Consensus Recommendation of "Hold" from Brokerages - March 6 at 3:22 PM
ResMed (RMD) Upgraded at Zacks Investment ResearchResMed (RMD) Upgraded at Zacks Investment Research - March 6 at 2:06 PM
Head-To-Head Analysis: ResMed (RMD) versus Mindray Medical International (MR)Head-To-Head Analysis: ResMed (RMD) versus Mindray Medical International (MR) - March 5 at 9:16 PM
WINTON GROUP Ltd Acquires 66,102 Shares of ResMed Inc. (RMD)WINTON GROUP Ltd Acquires 66,102 Shares of ResMed Inc. (RMD) - March 5 at 4:08 PM
ResMed Inc. (RMD) Stake Decreased by State of Tennessee Treasury DepartmentResMed Inc. (RMD) Stake Decreased by State of Tennessee Treasury Department - March 5 at 3:28 PM
Lombard Odier Asset Management Switzerland SA Has $3.21 Million Holdings in ResMed Inc. (RMD)Lombard Odier Asset Management Switzerland SA Has $3.21 Million Holdings in ResMed Inc. (RMD) - March 5 at 11:48 AM
Zacks: Analysts Anticipate ResMed Inc. (RMD) Will Announce Quarterly Sales of $562.33 MillionZacks: Analysts Anticipate ResMed Inc. (RMD) Will Announce Quarterly Sales of $562.33 Million - March 5 at 7:00 AM
American International Group Inc. Grows Position in ResMed Inc. (RMD)American International Group Inc. Grows Position in ResMed Inc. (RMD) - March 5 at 4:24 AM
Amalgamated Bank Acquires 1,476 Shares of ResMed Inc. (RMD)Amalgamated Bank Acquires 1,476 Shares of ResMed Inc. (RMD) - March 5 at 4:20 AM
ResMed (RMD) Stock Rating Upgraded by ValuEngineResMed (RMD) Stock Rating Upgraded by ValuEngine - March 4 at 3:19 PM
ResMed Inc. (RMD) Position Raised by Pittenger & Anderson Inc.ResMed Inc. (RMD) Position Raised by Pittenger & Anderson Inc. - March 3 at 4:22 PM
James Hollingshead Sells 600 Shares of ResMed Inc. (RMD) StockJames Hollingshead Sells 600 Shares of ResMed Inc. (RMD) Stock - March 2 at 7:14 PM
UBS Asset Management Americas Inc. Has $36.69 Million Holdings in ResMed Inc. (RMD)UBS Asset Management Americas Inc. Has $36.69 Million Holdings in ResMed Inc. (RMD) - February 28 at 5:36 PM
The Manufacturers Life Insurance Company  Increases Position in ResMed Inc. (RMD)The Manufacturers Life Insurance Company Increases Position in ResMed Inc. (RMD) - February 28 at 5:27 PM
ResMed (RMD) Upgraded to "Buy" by Zacks Investment ResearchResMed (RMD) Upgraded to "Buy" by Zacks Investment Research - February 28 at 11:26 AM
Norinchukin Bank The Acquires 761 Shares of ResMed Inc. (RMD)Norinchukin Bank The Acquires 761 Shares of ResMed Inc. (RMD) - February 27 at 12:46 PM
Schroder Investment Management Group Has $12.72 Million Stake in ResMed Inc. (RMD)Schroder Investment Management Group Has $12.72 Million Stake in ResMed Inc. (RMD) - February 27 at 11:52 AM
Reviewing Illumina (ILMN) & ResMed (RMD)Reviewing Illumina (ILMN) & ResMed (RMD) - February 27 at 11:42 AM
State of Wisconsin Investment Board Has $11.14 Million Position in ResMed Inc. (RMD)State of Wisconsin Investment Board Has $11.14 Million Position in ResMed Inc. (RMD) - February 25 at 9:30 AM
ResMed Inc. (RMD) Shares Sold by Bank of New York Mellon CorpResMed Inc. (RMD) Shares Sold by Bank of New York Mellon Corp - February 25 at 4:32 AM
Why Is ResMed (RMD) Down 7.5% Since the Last Earnings Report?Why Is ResMed (RMD) Down 7.5% Since the Last Earnings Report? - February 21 at 5:06 PM
ResMed (RMD) Rating Lowered to Hold at Zacks Investment ResearchResMed (RMD) Rating Lowered to Hold at Zacks Investment Research - February 21 at 2:11 PM
ResMed (RMD) Upgraded to Buy by Zacks Investment ResearchResMed (RMD) Upgraded to Buy by Zacks Investment Research - February 20 at 3:07 PM
Insider Selling: ResMed Inc. (RMD) CFO Sells 2,000 Shares of StockInsider Selling: ResMed Inc. (RMD) CFO Sells 2,000 Shares of Stock - February 16 at 10:02 PM
ResMed Inc. (RMD) Expected to Announce Quarterly Sales of $562.33 MillionResMed Inc. (RMD) Expected to Announce Quarterly Sales of $562.33 Million - February 16 at 6:08 AM
ResMed Inc. (RMD) Receives Consensus Rating of "Hold" from BrokeragesResMed Inc. (RMD) Receives Consensus Rating of "Hold" from Brokerages - February 9 at 5:50 PM
GEMCO Medical Announces Brightree PartnershipGEMCO Medical Announces Brightree Partnership - February 8 at 8:32 AM
ResMed Inc. (RMD) Insider Sells $200,240.00 in StockResMed Inc. (RMD) Insider Sells $200,240.00 in Stock - February 5 at 3:26 PM
ResMed (RMD) Downgraded by Zacks Investment Research to HoldResMed (RMD) Downgraded by Zacks Investment Research to Hold - February 5 at 3:18 PM
ResMed Inc. (RMD) CFO Sells $125,162.50 in StockResMed Inc. (RMD) CFO Sells $125,162.50 in Stock - February 2 at 9:44 PM
ResMed (RMD) Upgraded by Zacks Investment Research to BuyResMed (RMD) Upgraded by Zacks Investment Research to Buy - February 2 at 4:56 PM
I'm very bullish on all the tech earnings this week: NYSE traderI'm very bullish on all the tech earnings this week: NYSE trader - February 1 at 4:01 PM
John P. Wareham Sells 25,934 Shares of ResMed Inc. (RMD) StockJohn P. Wareham Sells 25,934 Shares of ResMed Inc. (RMD) Stock - January 29 at 3:14 PM
Zacks: Brokerages Anticipate ResMed Inc. (RMD) Will Post Earnings of $0.83 Per ShareZacks: Brokerages Anticipate ResMed Inc. (RMD) Will Post Earnings of $0.83 Per Share - January 28 at 3:18 PM
Traders Buy Large Volume of Call Options on ResMed (RMD)Traders Buy Large Volume of Call Options on ResMed (RMD) - January 27 at 1:44 AM
Insider Selling: ResMed Inc. (RMD) Director Sells 4,885 Shares of StockInsider Selling: ResMed Inc. (RMD) Director Sells 4,885 Shares of Stock - January 25 at 3:10 PM
ResMed Inc. (RMD) to Post FY2018 Earnings of $3.30 Per Share, Jefferies Group ForecastsResMed Inc. (RMD) to Post FY2018 Earnings of $3.30 Per Share, Jefferies Group Forecasts - January 25 at 12:18 PM
Operating Leverage Drives ResMed's Profits HigherOperating Leverage Drives ResMed's Profits Higher - January 24 at 4:18 PM
ResMed Inc. to Post Q3 2018 Earnings of $0.79 Per Share, William Blair Forecasts (RMD)ResMed Inc. to Post Q3 2018 Earnings of $0.79 Per Share, William Blair Forecasts (RMD) - January 24 at 1:32 PM
ResMed Inc. to Post Q3 2018 Earnings of $0.79 Per Share, Jefferies Group Forecasts (RMD)ResMed Inc. to Post Q3 2018 Earnings of $0.79 Per Share, Jefferies Group Forecasts (RMD) - January 24 at 1:32 PM
Active-Investors: Free Research Report as ResMeds Revenue Jumped 13% and Non-GAAP EPS Soared 37%Active-Investors: Free Research Report as ResMed's Revenue Jumped 13% and Non-GAAP EPS Soared 37% - January 24 at 10:10 AM
Resmed Inc. (RMD) Has Soared To A New High On Strong Q2 EarningsResmed Inc. (RMD) Has Soared To A New High On Strong Q2 Earnings - January 24 at 10:10 AM
ResMed: S&P 500’s Top Gainer on January 23ResMed: S&P 500’s Top Gainer on January 23 - January 24 at 10:10 AM

SEC Filings

ResMed (NYSE:RMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


ResMed (NYSE:RMD) Income Statement, Balance Sheet and Cash Flow Statement


ResMed (NYSE RMD) Stock Chart for Friday, March, 23, 2018

Loading chart…

This page was last updated on 3/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.